These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32934302)

  • 1. In vitro validation of the tear matrix metalloproteinase 9 in-situ immunoassay.
    Bang SP; Son MJ; Kim H; Lee YH; Jun JH
    Sci Rep; 2020 Sep; 10(1):15126. PubMed ID: 32934302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the Matrix Metalloproteinase 9 Point-of-Care Test Positivity According to MMP-9 Concentration and Loading Volume.
    Huh J; Choi SY; Eom Y; Kim HM; Song JS
    Cornea; 2020 Feb; 39(2):234-236. PubMed ID: 31369458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of tear volume for positivity of tear matrix metalloproteinase-9 immunoassay.
    Jun JH; Lee YH; Son MJ; Kim H
    PLoS One; 2020; 15(7):e0235408. PubMed ID: 32649686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay.
    Messmer EM; von Lindenfels V; Garbe A; Kampik A
    Ophthalmology; 2016 Nov; 123(11):2300-2308. PubMed ID: 27665213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of point-of-care test for elevated tear matrix metalloproteinase 9 in post-LASIK dry eyes.
    Chan TC; Ye C; Chan KP; Chu KO; Jhanji V
    Br J Ophthalmol; 2016 Sep; 100(9):1188-91. PubMed ID: 26682569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunoassay for matrix metalloproteinase-9 in the tear film of patients with pseudoexfoliation syndrome - a pilot study].
    Zimmermann N; Erb C
    Klin Monbl Augenheilkd; 2013 Aug; 230(8):804-7. PubMed ID: 23670526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye.
    Sambursky R; Davitt WF; Latkany R; Tauber S; Starr C; Friedberg M; Dirks MS; McDonald M
    JAMA Ophthalmol; 2013 Jan; 131(1):24-8. PubMed ID: 23307206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tear Martix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Post-Lasik Ectasia.
    Elmohamady MN; Abdelghaffar W; Salem TI
    Int Ophthalmol; 2019 Mar; 39(3):631-637. PubMed ID: 29478225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of Tear Film Osmolarity and 2 Different MMP-9 Tests With Common Dry Eye Tests in a Cohort of Non-Dry Eye Patients.
    Schargus M; Ivanova S; Kakkassery V; Dick HB; Joachim S
    Cornea; 2015 Jul; 34(7):739-44. PubMed ID: 25909238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diurnal variation of matrix metalloproteinase-9 and its associated factors in human tears.
    Markoulli M; Papas E; Cole N; Holden BA
    Invest Ophthalmol Vis Sci; 2012 Mar; 53(3):1479-84. PubMed ID: 22323468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tear levels and activity of matrix metalloproteinase (MMP)-1 and MMP-9 in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Abatangelo G; Plebani M; Secchi AG
    Invest Ophthalmol Vis Sci; 2003 Jul; 44(7):3052-8. PubMed ID: 12824251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant.
    Sobrin L; Liu Z; Monroy DC; Solomon A; Selzer MG; Lokeshwar BL; Pflugfelder SC
    Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1703-9. PubMed ID: 10845589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective, multicenter, clinical evaluation of point-of-care matrix metalloproteinase-9 test for confirming dry eye disease.
    Sambursky R; Davitt WF; Friedberg M; Tauber S
    Cornea; 2014 Aug; 33(8):812-8. PubMed ID: 24977985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of reliability and validity of the 5-scale grading system of the point-of-care immunoassay for tear matrix metalloproteinase-9.
    Kim M; Oh JY; Bae SH; Lee SH; Lee WJ; Chun YS; Kim KW
    Sci Rep; 2021 Jun; 11(1):12394. PubMed ID: 34117341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tear MMP-9 levels as a marker of ocular surface inflammation in conjunctivochalasis.
    Acera A; Vecino E; Duran JA
    Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):8285-91. PubMed ID: 24255042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in tear biomarker levels in keratoconus after corneal collagen crosslinking.
    Recalde JI; Duran JA; Rodriguez-Agirretxe I; Soria J; Sanchez-Tena MA; Pereiro X; Suarez T; Acera A
    Mol Vis; 2019; 25():12-21. PubMed ID: 30804658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of contact lens wear on the diurnal profile of matrix metalloproteinase 9 in tears.
    Markoulli M; Papas E; Cole N; Holden B
    Optom Vis Sci; 2013 May; 90(5):419-29. PubMed ID: 23563442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional Activity of Matrix Metalloproteinases 2 and 9 in Tears of Patients With Glaucoma.
    Sahay P; Rao A; Padhy D; Sarangi S; Das G; Reddy MM; Modak R
    Invest Ophthalmol Vis Sci; 2017 May; 58(6):BIO106-BIO113. PubMed ID: 28586796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An automated nanoparticle-based homogeneous immunoassay for determining docetaxel concentrations in plasma.
    Cline DJ; Zhang H; Lundell GD; Harney RL; Riaz HK; Jarrah J; Li Y; Miyazaki M; Courtney JB; Baburina I; Salamone SJ
    Ther Drug Monit; 2013 Dec; 35(6):803-8. PubMed ID: 24263639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tear Osmolarity and Matrix Metallopeptidase-9 in Dry Eye Associated with Sjögren's Syndrome.
    Kook KY; Jin R; Li L; Yoon HJ; Yoon KC
    Korean J Ophthalmol; 2020 Jun; 34(3):179-186. PubMed ID: 32495525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.